0001209191-23-038409.txt : 20230620 0001209191-23-038409.hdr.sgml : 20230620 20230620163110 ACCESSION NUMBER: 0001209191-23-038409 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230615 FILED AS OF DATE: 20230620 DATE AS OF CHANGE: 20230620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Molineaux Christopher P. CENTRAL INDEX KEY: 0001654773 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 231025636 MAIL ADDRESS: STREET 1: C/O ACLARIS THERAPEUTICS, INC. STREET 2: 101 LINDENWOOD DRIVE, SUITE 400 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-15 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001654773 Molineaux Christopher P. C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 1 0 0 0 0 Common Stock 2023-06-15 4 M 0 51 0.72 A 31805 D Common Stock 2023-06-15 4 M 0 198 1.52 A 32003 D Stock Option (right to buy) 0.72 2023-06-15 4 M 0 51 0.00 D 2024-08-12 Common Stock 51 0 D Stock Option (right to buy) 1.52 2023-06-15 4 M 0 198 0.00 D 2024-12-07 Common Stock 198 0 D 25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. 25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. /s/ Mark Ballantyne, Attorney-in-Fact 2023-06-20